th percentiles) age at presentation was earliest for MPE (1.45yrs (0.9,4.3)), followed by urticaria (1.8yrs (1.1,5.2)), then SSLR (2.5yrs (1.6,5.0)) (p50.01). Day of onset post-antibiotic initiation was bimodal for MPE; whereas urticaria and SSLR had unimodal peaks at days 7 and 8 respectively (p<0.0001). Patients with SSLR had higher rates of associated angioedema and fever and more frequently received oral steroids and returned to the ED (p<0.0001). CONCLUSIONS: We characterized for the first time a pediatric cohort of ED patients with AAR notable for their young age and at least 3 distinct clinical phenotypes. Prospective studies are needed to determine the rate of tolerance with amoxicillin re-exposure following ED AAR, particularly in patients with SSLR, which were more common than expected.
Skin Test Boosting Effect In Amoxicillin Allergic Children
Roxane Labrosse, MD Department of Pediatrics, Service of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada. RATIONALE: Non-immediate drug hypersensitivity (NIDH) to amoxicillin is prevalent in the pediatric population. Even though skin tests (ST) are usually performed to assess beta-lactam hypersensitivity, their predictive value are of limited help in this particular population. Since a boosting effect following a recent NIDH reaction is physiologically plausible in T cell-mediated immunity, we assessed the predictive value of a repeated ST in this population. METHODS: The sample consisted of consecutive children evaluated for a history suggestive of hypersensitivity to amoxicillin between February 2015 and May 2017. Investigation was first performed by prick and intradermal ST with penicilloyl-polylysine (PPL) and benzylpenicillin (BP). Patients then underwent drug provocation test (DPT) to amoxicillin (45 mg/kg) in the allergy outpatient clinic followed, if necessary, by a fourday ambulatory course. Patients presenting a positive amoxicillin DPT were scheduled for a cephalosporin DPT, and ST were repeated then. RESULTS: We evaluated 1 156 children and amoxicillin NIDH was confirmed by DPT in 49 (4,2%; 95% CI 3.2-5.6). All patients presented a mild to moderate NIDH. Skin tests were first performed in 26 of them and then repeated in 9 patients. Results of ST were negative (immediate and delayed) in both assessments, yielding a positive predictive value for repeated ST of 0,0% ( 95% CI 0.0-34.5). CONCLUSIONS: We did not observe any boosting effect by repeating ST in pediatric patients presenting mild to moderate amoxicillin NIDH. Moreover, our cohort strengthens the idea that ST are of limited contribution in this population.
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Elevated tryptase during aspirin desensitization in aspirin-exacerbated respiratory disease Blanka Kaplan, MD FAAAAI; Northwell Health, Great Neck, NY. RATIONALE: Reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) in aspirin-exacerbated respiratory disease (AERD) are classified as pseudoallergic and thought to be caused by non IgE-mediated, nonimmunologic mast cell activation. Aspirin desensitization, followed by long-term daily aspirin therapy in AERD has been shown to reduce regrowth of nasal polyps and decrease requirement of oral steroids. METHODS: Retrospective chart review of patients who underwent aspirin desensitization for AERD was performed and patients with severe manifestations were selected. RESULTS: Total of 21 patients with AERD underwent outpatient aspirin desensitization as per published recommendations. All patients were pretreated with leukotriene receptor antagonists and H1-antihistamines. During desensitization three of these patients developed significant adverse effects, involving multiple systems and had tryptase measured. Clinical manifestations included severe, intractable gastrointestinal (abdominal cramping/pain, vomiting, diarrhea), respiratory (cough, dyspnea, nasal congestion) and cutaneous symptoms (pruritic rash). Gastrointestinal symptoms were predominant and protracted. None of the patients developed hypotension. All three patients had significantly elevated tryptase (13.7-17.2 ng/ml), compared to basal level (4.1-7.2 ng/ml). Two of these patients successfully completed aspirin desensitization and continued daily treatment with high-dose aspirin. One patient declined to complete aspirin desensitization. CONCLUSIONS: It is important to remember that mast cell activation/ degranulation can be a feature of pseudoallergic reactions as well as in IgEmediated allergic reactions. Patients with AERD can develop mast cell activation/degranulation with release of tryptase during aspirin challenge/ desensitization. It appears that the presence of gastrointestinal symptoms during aspirin desensitization in AERD may be indicative of significant mast cell degranulation.
